Peptide Record

Retatrutide · Metabolic · graded 2026-07-30

Weight & fat loss

This grade describes how much evidence exists for Retatrutide against weight & fat loss — not whether it works, and not whether it is safe. It is computed from the inputs below by a fixed rule with no editorial adjustment.

Why this grade

Not hidden behind a control — showing the work is the point
Score decomposition — every input and its contribution
ComponentPointsScale
Best study type
The strongest design that produced evidence for this outcome, not the average design.
+5Human RCT 5 · Human observational 4 · Animal 2 · Preclinical 1 · None 0
Largest human sample
Largest single human study, not a pooled total across studies.
+3n ≥ 200 → 3 · 50–199 → 2 · < 50 → 1 · no human study → 0
Independent replication
Distinct research groups at the best study tier above, resolved through author and institution records.
+3≥ 3 groups → 3 · 2 → 2 · 1 → 1 · 0 → 0
Directional consistency
Share of studies at the best study tier reporting effect in the same direction — the same studies the replication row counts, not every record on the pair.
Measured over 1 stated direction across 17 studies at the best tier. A ratio over three readings and the same ratio over ninety are the same number and are not the same evidence.
0≥ 90% concordant → 3 · ≥ 70% → 2 · ≥ 50% → 1 · below → 0 · fewer than 3 readings → 0
Bias risk
A deduction, never a bonus. A flag is counted only where a record states one; silence is not a pass and is not a flag.
-3−1 per flag, floor −3: industry funding · no preregistration · no blinding
Total8Sum of the rows above, floored at 0.
What the bias row had to work with — how many of this pair’s records disclosed each field at all
FieldFlag statedStated the oppositeNot statedSilent
industry_funded
industry-funded deducts a point; declared non-commercial does not; silence does neither.
1514975%
preregistered
not preregistered deducts a point; preregistered does not; silence does neither.
1154975%
blinded
not blinded deducts a point; blinded does not; silence does neither.
2135077%

Grade A additionally requires a total of at least 11 and replication of at least 2: a high score carried by one research group is not replicated evidence, however large the trial.

Doses administered in studies

Sourced figures, not a protocol

Studied doses — not yet collected

Dose, route and n are extracted from study full text, and full text is paywalled for most records in this corpus. No dose has been extracted for this pair yet. Read that as an extraction gap, not as evidence that the studies below administered nothing.

This is a gap in our collection, not a finding about studied doses. Read it as “we have not looked yet”, never as “there is nothing there”. How extraction works and where it fails

Cited sources

65 records · ordered by source hierarchy

These are the records the grade above was computed from — the same set, by the same rule, read from one definition shared with the grader. Records attributed to an alias for a materially different product are not among them; where this pair has any, they are listed separately below.

  • HUMAN-TRIAL17
  • ANIMAL5
  • PRECLINICAL43
SourceStudyDesignnBias flagsDate
HUMAN-TRIALA Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight
NCT05929066 · matched on "LY-3437943"
human-rct2335industry-funded—
HUMAN-TRIALA Study of Retatrutide (LY3437943) in Participants With Type 2 Diabetes Mellitus Who Have Obesity or Overweight
NCT05929079 · matched on "LY-3437943"
human-rct1000industry-funded—
HUMAN-TRIALA Study of Retatrutide (LY3437943) Compared to Tirzepatide (LY3298176) in Adults Who Have Obesity
NCT06662383 · matched on "LY-3437943"
human-rct800industry-funded—
HUMAN-TRIALA Study of Retatrutide (LY3437943) in the Maintenance of Weight Reduction in Individuals With Obesity
NCT06859268 · matched on "LY-3437943"
human-rct643industry-funded—
HUMAN-TRIALA Study of Retatrutide (LY3437943) in Participants Without Type 2 Diabetes Who Have Obesity or Overweight
NCT07357415 · matched on "LY-3437943"
human-rct600industry-funded—
HUMAN-TRIALA Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight and Chronic Low Back Pain
NCT07035093 · matched on "LY-3437943"
human-rct586industry-funded—
HUMAN-TRIALA Study of Retatrutide (LY3437943) Once Weekly in Participants Who Have Obesity or Overweight and Osteoarthritis of the Knee
NCT05931367 · matched on "LY-3437943"
human-rct445industry-funded—
HUMAN-TRIALA Study of LY3437943 in Participants Who Have Obesity or Are Overweight
NCT04881760 · matched on "LY-3437943"
human-rct338industry-funded—
HUMAN-TRIALEffect of LY3437943 Versus Placebo in Participants Who Have Obesity or Are Overweight
NCT07467447 · matched on "LY-3437943"
human-rct300industry-funded, not preregistered—
HUMAN-TRIALA Study of Retatrutide (LY3437943) in Participants With Obesity or Overweight
NCT07232719 · matched on "LY-3437943"
human-rct250industry-funded—
HUMAN-TRIALA Study to Measure Calorie Consumption and Usage in Participants With Obesity Using LY3437943
NCT06313528 · matched on "LY-3437943"
human-rct85industry-funded—
HUMAN-TRIALLY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trial.
PMID 36354040 · DOI 10.1016/s0140-6736(22)02033-5 · matched on "LY3437943"
human-rct72industry-funded2022-11-26
HUMAN-TRIALA Study of LY3437943 in Postmenopausal Female Participants Who Are Overweight or Obese
NCT06039826 · matched on "LY-3437943"
human-observational46industry-funded, not blinded—
HUMAN-TRIALA Drug-Drug Interaction (DDI) Study of LY3437943 in Obese Participants
NCT05445232 · matched on "LY-3437943"
human-observational32industry-funded, not blinded—
HUMAN-TRIALA Study of LY3437943 in Chinese Participants With Obesity Or Overweight
NCT05548231 · matched on "LY-3437943"
human-rct32industry-funded—
HUMAN-TRIALTriple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial.
PMID 38858523 · DOI 10.1038/s41591-024-03018-2 · matched on "Retatrutide"
human-rct—none stated2024-07-01
HUMAN-TRIALTriple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial.
PMID 37366315 · DOI 10.1056/nejmoa2301972 · matched on "LY3437943"
human-rct—none stated2023-08-10
ANIMALGIPR:GCGR co-agonism restores normal weight in obese rodents.
PMID 41997446 · DOI 10.1016/j.molmet.2026.102365 · matched on "Retatrutide"
animal—none stated2026-06-01
ANIMALRetatrutide Shows Multiple Metabolic Benefits in Diet-Induced Obese MASH Mouse and Hamster Models.
PMID 41741376 · DOI 10.1002/oby.70155 · matched on "Retatrutide"
animal—none stated2026-06-01
ANIMALKynurenic acid mediates epicardial fat-induced lymphatic metabolic dysfunction in atrial fibrillation.
PMID 42156758 · DOI 10.1038/s41467-026-72974-9 · matched on "LY3437943"
animal—none stated2026-05-19
ANIMALEfficacy of GLP-1 analog peptides, semaglutide, tirzepatide, and retatrutide on MC4R deficient obesity and their comparison.
PMID 41723268 · DOI 10.1038/s41366-026-02025-2 · matched on "Retatrutide"
animal—none stated2026-04-01
ANIMALLY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept.
PMID 35985340 · DOI 10.1016/j.cmet.2022.07.013 · matched on "LY3437943"
animal—none stated2022-09-06
PRECLINICALEfficacy and Safety of GLP-1 Receptor Agonists, Dual Agonists, and Retatrutide for Weight Loss in Adults With Overweight or Obesity: A Bayesian NMA.
PMID 40685589 · DOI 10.1002/oby.24360 · matched on "Retatrutide"
not determined29506none stated2025-11-01
PRECLINICALEfficacy and Safety of Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss Among Adults Without Diabetes : A Systematic Review of Randomized Controlled Trials.
PMID 39761578 · DOI 10.7326/annals-24-01590 · matched on "Retatrutide"
not determined15491none stated2025-02-01
PRECLINICALBeyond weight loss: multisystem benefits of obesity medications.
PMID 42208956 · DOI 10.1016/s2213-8587(26)00100-2 · matched on "Retatrutide"
not determined—none stated2026-08-01
PRECLINICALComparative effects of drugs for adults with overweight or obesity: systematic review and network meta-analysis.
PMID 42419792 · DOI 10.1136/bmj-2026-372161 · matched on "Retatrutide"
not determined—none stated2026-07-08
PRECLINICALSynergistic Intervention for Obesity: Integrating Central Appetite Regulation and Peripheral Energy Expenditure.
PMID 42249250 · DOI 10.1007/s13679-026-00722-7 · matched on "Retatrutide"
not determined—none stated2026-06-06
PRECLINICALChildhood obesity and cardiac risk in youth: Emerging challenges toward 2050.
PMID 41933725 · DOI 10.1016/j.clnesp.2026.103260 · matched on "Retatrutide"
not determined—none stated2026-06-01
PRECLINICALA retrospective audit of weight loss and health outcomes following bariatric surgery at a tertiary public hospital.
PMID 42142983 · DOI 10.1016/j.orcp.2026.05.003 · matched on "Retatrutide"
not determined—none stated2026-05-01
PRECLINICALNew Drugs on the Block: Dietary Management and Nutritional Considerations During the Use of Anti-Obesity Medication.
PMID 41901137 · DOI 10.3390/nu18060962 · matched on "Retatrutide"
not determined—none stated2026-03-18
PRECLINICALDevelopment and Content Evaluation of the Eating Behavior and Appetite Questionnaire (EBAQ) for Individuals with Obesity.
PMID 41201783 · DOI 10.1007/s12325-025-03386-2 · matched on "Retatrutide"
not determined—none stated2026-01-01
PRECLINICALThe Triple-Agonist Revolution: Retatrutide and the Paradigm Shift in Multi-Hormonal Pharmacotherapy for Obesity and Cardiometabolic Comorbidities.
PMID 41545327 · DOI 10.1002/cpdd.70001 · matched on "LY3437943"
not determined—none stated2026-01-01
PRECLINICALGastrointestinal Adverse Effects of Anti-Obesity Medications in Non-Diabetic Adults: A Systematic Review.
PMID 41303824 · DOI 10.3390/medicina61111987 · matched on "Retatrutide"
not determined—none stated2025-11-05
PRECLINICALWeight management treatment in obesity.
PMID 40865172 · DOI 10.1016/j.medcli.2025.107152 · matched on "retatrutida"
not determined—none stated2025-11-01
PRECLINICALEfficacy and safety of anti-obesity drugs in metabolic dysfunction-associated steatotic liver disease: An updated review.
PMID 41025003 · DOI 10.3748/wjg.v31.i37.111435 · matched on "Retatrutide"
not determined—none stated2025-10-07
PRECLINICALGlucagon-like peptide-1 receptor analogues and beyond: emerging obesity pharmacotherapies.
PMID 40728225 · DOI 10.23736/s0031-0808.25.05339-x · matched on "Retatrutide"
not determined—none stated2025-09-01
PRECLINICALEfficacy and safety of retatrutide for the treatment of obesity: a systematic review of clinical trials.
PMID 40728138 · DOI 10.1515/jbcpp-2025-0113 · matched on "Retatrutide"
not determined—none stated2025-07-01
PRECLINICALAntiobesity medications in adult and pediatric obesity and metabolic dysfunction-associated steatotic liver disease.
PMID 40554267 · DOI 10.1016/j.pharmr.2025.100058 · matched on "Retatrutide"
not determined—none stated2025-07-01
PRECLINICALRetatrutide-A Game Changer in Obesity Pharmacotherapy.
PMID 40563436 · DOI 10.3390/biom15060796 · matched on "Retatrutide"
not determined—none stated2025-05-30
PRECLINICALBreaking the weight loss paradox: from weight reduction to cardiovascular benefit in obesity treatment.
PMID 40126003 · DOI 10.20452/pamw.16983 · matched on "Retatrutide"
not determined—none stated2025-03-24
PRECLINICALPharmacological Dissection Identifies Retatrutide Overcomes the Therapeutic Barrier of Obese TNBC Treatments through Suppressing the Interplay between Glycosylation and Ubiquitylation of YAP.
PMID 39868848 · DOI 10.1002/advs.202407494 · matched on "Retatrutide"
not determined—none stated2025-03-01
PRECLINICALThe promise of glucagon-like peptide 1 receptor agonists (GLP-1RA) for the treatment of obesity: a look at phase 2 and 3 pipelines.
PMID 40022548 · DOI 10.1080/13543784.2025.2472408 · matched on "Retatrutide"
not determined—none stated2025-03-01
PRECLINICALWhat is the pipeline for future medications for obesity?
PMID 38302593 · DOI 10.1038/s41366-024-01473-y · matched on "Retatrutide"
not determined—none stated2025-03-01
PRECLINICALHarnessing GLP-1 Receptor Agonists for Obesity Treatment: Prospects and Obstacles on the Horizon.
PMID 41333115 · DOI 10.1155/jobe/9919810 · matched on "Retatrutide"
not determined—none stated2025-01-01
PRECLINICALEfficacy and safety of triple hormone receptor agonist retatrutide for the management of obesity: a systematic review and meta-analysis.
PMID 39817343 · DOI 10.1080/17512433.2025.2450254 · matched on "LY3437943"
not determined—none stated2025-01-01
PRECLINICALWeight Loss Blockbuster Development: A Role for Unimolecular Polypharmacology.
PMID 39259982 · DOI 10.1146/annurev-pharmtox-061324-011832 · matched on "Retatrutide"
not determined—none stated2025-01-01
PRECLINICALEmerging pharmacotherapies for obesity: A systematic review.
PMID 39952695 · DOI 10.1124/pharmrev.123.001045 · matched on "Retatrutide"
not determined—none stated2025-01-01
PRECLINICALThe impact of weight loss on fat-free mass, muscle, bone and hematopoiesis health: Implications for emerging pharmacotherapies aiming at fat reduction and lean mass preservation.
PMID 39481534 · DOI 10.1016/j.metabol.2024.156057 · matched on "Retatrutide"
not determined—none stated2024-12-01
PRECLINICALSeven glucagon-like peptide-1 receptor agonists and polyagonists for weight loss in patients with obesity or overweight: an updated systematic review and network meta-analysis of randomized controlled trials.
PMID 39305981 · DOI 10.1016/j.metabol.2024.156038 · matched on "Retatrutide"
not determined—none stated2024-12-01
PRECLINICALIncretin-Based Weight Loss Pharmacotherapy: Can Resistance Exercise Optimize Changes in Body Composition?
PMID 38687506 · DOI 10.2337/dci23-0100 · matched on "Retatrutide"
not determined—none stated2024-10-01
PRECLINICALPharmacological Treatment of Binge Eating Disorder and Frequent Comorbid Diseases.
PMID 39096466 · DOI 10.1007/s40263-024-01111-1 · matched on "Retatrutide"
not determined—none stated2024-09-01
PRECLINICALInvestigational and emerging gastric inhibitory polypeptide (GIP) receptor-based therapies for the treatment of obesity.
PMID 38984950 · DOI 10.1080/13543784.2024.2377319 · matched on "Retatrutide"
not determined—none stated2024-08-01
PRECLINICALMolecular Mechanisms behind Obesity and Their Potential Exploitation in Current and Future Therapy.
PMID 39125772 · DOI 10.3390/ijms25158202 · matched on "Retatrutide"
not determined—none stated2024-07-27
PRECLINICALSex, race, and BMI in clinical trials of medications for obesity over the past three decades: a systematic review.
PMID 38723646 · DOI 10.1016/s2213-8587(24)00098-6 · matched on "Retatrutide"
not determined—none stated2024-06-01
PRECLINICALAdvancements in the management of obesity: a review of current evidence and emerging therapies.
PMID 38685693 · DOI 10.1080/17446651.2024.2347258 · matched on "Retatrutide"
not determined—none stated2024-05-01
PRECLINICALA review of an investigational drug retatrutide, a novel triple agonist agent for the treatment of obesity.
PMID 38367045 · DOI 10.1007/s00228-024-03646-0 · matched on "Retatrutide"
not determined—none stated2024-05-01
PRECLINICALRare genetic forms of obesity in childhood and adolescence: A narrative review of the main treatment options with a focus on innovative pharmacological therapies.
PMID 38227053 · DOI 10.1007/s00431-024-05427-4 · matched on "Retatrutide"
not determined—none stated2024-04-01
PRECLINICALAn overview of therapeutic options of obesity management in India: the Integrated Diabetes and Endocrinology Academy (IDEA) 2023 Congress update.
PMID 38471973 · DOI 10.1080/17512433.2024.2330468 · matched on "Retatrutide"
not determined—none stated2024-04-01
PRECLINICALReview article: Pharmacologic management of obesity - updates on approved medications, indications and risks.
PMID 38169126 · DOI 10.1111/apt.17856 · matched on "Retatrutide"
not determined—none stated2024-02-01
PRECLINICALAdvances in obesity pharmacotherapy; learning from metabolic surgery and beyond.
PMID 37995806 · DOI 10.1016/j.metabol.2023.155741 · matched on "Retatrutide"
not determined—none stated2024-02-01
PRECLINICALThe Road towards Triple Agonists: Glucagon-Like Peptide 1, Glucose-Dependent Insulinotropic Polypeptide and Glucagon Receptor - An Update.
PMID 38356208 · DOI 10.3803/enm.2024.1942 · matched on "Retatrutide"
not determined—none stated2024-02-01
PRECLINICALTriple-Hormone-Receptor Agonist Retatrutide for Obesity.
PMID 37888925 · DOI 10.1056/nejmc2310645 · matched on "Retatrutide"
not determined—none stated2023-10-26
PRECLINICALTriple-Hormone-Receptor Agonist Retatrutide for Obesity.
PMID 37888926 · DOI 10.1056/nejmc2310645 · matched on "Retatrutide"
not determined—none stated2023-10-26
PRECLINICALTriple-Hormone-Receptor Agonist Retatrutide for Obesity. Reply.
PMID 37888927 · DOI 10.1056/nejmc2310645 · matched on "Retatrutide"
not determined—none stated2023-10-26
PRECLINICALTriple-Hormone Combination Retatrutide Induces 24% Body Weight Loss.
PMID 37405802 · DOI 10.1001/jama.2023.12055 · matched on "Retatrutide"
not determined—none stated2023-07-25

Rows are ordered by source hierarchy, so nothing below a regulatory filing appears above a human trial. A field marked uncertain is one where the extraction passes disagreed; it publishes as unknown rather than as a picked winner. A design reading “not determined” is a design nothing established, not a design of none. Explore the full corpus for Retatrutide